TFRC and brain cancer: Transferrin receptors are highly expressed in brain cancers and conjugation of ASOs with anti-transferrin receptor monoclonal antibodies showed a threefold increase in cellular uptake compared to naked ASOs and twofold higher than ASOs conjugated with an aspecific IgG antibody [129].